Therapeutic Response

BRCA1 oncogenic variants status confers therapeutic sensitivity to Abiraterone acetate in combination with Niraparib and Prednisolone in patients with Prostate Adenocarcinoma.

Statements

Source and description
Akeega (abiraterone acetate and niraparib) [product information]. EMA. The European Medicines Agency (EMA) has authorized niraparib with abiraterone acetate in combination with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.